LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Cerrado

SectorSanidad

140.29 0.24

Resumen

Variación precio

24h

Actual

Mínimo

140.04

Máximo

141.94

Métricas clave

By Trading Economics

Ingresos

394M

635M

Ventas

215M

2.6B

P/B

Media del Sector

12.653

35.733

BPA

3.02

Margen de beneficios

23.995

Empleados

7,605

EBITDA

457M

1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+20.72% upside

Dividendos

By Dow Jones

Próximas Ganancias

29 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

442M

19B

Apertura anterior

140.05

Cierre anterior

140.29

Noticias sobre sentimiento de mercado

By Acuity

31%

69%

92 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Biogen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 sept 2025, 09:30 UTC

Adquisiciones, fusiones, absorciones

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 sept 2025, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

5 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

5 sept 2025, 20:37 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 sept 2025, 20:37 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 sept 2025, 20:36 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 sept 2025, 20:36 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 sept 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 sept 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 sept 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 sept 2025, 20:20 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 sept 2025, 19:22 UTC

Ganancias

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 sept 2025, 19:17 UTC

Charlas de Mercado

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 sept 2025, 18:59 UTC

Ganancias

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept 2025, 18:35 UTC

Charlas de Mercado

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 sept 2025, 17:25 UTC

Charlas de Mercado

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 sept 2025, 17:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 sept 2025, 17:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 sept 2025, 17:17 UTC

Charlas de Mercado

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 sept 2025, 17:03 UTC

Charlas de Mercado

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 sept 2025, 16:39 UTC

Adquisiciones, fusiones, absorciones

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 sept 2025, 16:39 UTC

Adquisiciones, fusiones, absorciones

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 sept 2025, 16:39 UTC

Adquisiciones, fusiones, absorciones

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 sept 2025, 16:39 UTC

Adquisiciones, fusiones, absorciones

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 sept 2025, 16:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Equities Roundup: Market Talk

5 sept 2025, 16:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

5 sept 2025, 16:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 sept 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

5 sept 2025, 16:16 UTC

Ganancias

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Biogen Inc previsión

Precio Objetivo

By TipRanks

20.72% repunte

Estimación a 12 Meses

Media 169.81 USD  20.72%

Máximo 260 USD

Mínimo 118 USD

De acuerdo con 26 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Biogen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

26 ratings

12

Comprar

14

Mantener

0

Vender

Puntuación técnica

By Trading Central

118.15 / 121.17Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

92 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat